About
Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation.
What We Did
The second version of LIXTE has an updated logo and a more inviting color scheme. We love this image of DNA, and a product pipeline diagram shows the drugs progress.